Kiadis Pharma announces new data on ex-vivo FC21 expanded NK-cell therapy in 13 patients with relapsed/refractory acute myelo...
10 Março 2020 - 4:30AM
Kiadis Pharma announces new data on ex-vivo FC21 expanded NK-cell
therapy in 13 patients with relapsed/refractory acute myeloid
leukemia will be presented at the European Society for Blood and
Marrow Transplantation Annual Meeting*
EBMT Abstract #A-1137-0005-00784
Amsterdam, The Netherlands, March 10, 2020 – Kiadis
Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam
and Brussels: KDS), a clinical stage biopharmaceutical
company, today announces an abstract showcasing the potential of
the Company’s NK cell therapy to treat relapsed/refractory acute
myeloid leukemia (R/R AML) has been accepted for an oral
presentation at the 46th Annual Meeting of the European Society for
Blood and Marrow Transplantation (EBMT). Lucia Mariano da Rocha
Silla, MD, PhD, will present the data at EBMT, which is taking
place 30 August – 2 September in Madrid, Spain. These data are from
a Phase I study conducted by Dr. Silla at Hospital de Clínicas de
Porto Alegre (HCPA) in Brazil. In this study, sponsored by the
Brazilian Agencies for Research development, the adoptive transfer
of haploidentical expanded NK cells to restore NK cell numbers and
anti-leukemia function in patients with relapsed/refractory AML was
investigated.
Presentation Details
Title: Phase 1 Study of Adoptive Transfer of
Haploidentical Expanded NK Cells
Presenter: Lucia Mariano da Rocha Silla, MD,
PhD
Abstract #: #A-1137-0005-00784
(https://www.professionalabstracts.com/ebmt2020/iPlanner/#/presentation/817)
Session Name: OS6 session 6 - Cellular therapy
other than CARs
*EBMT has postponed its 46th Annual Meeting from March
2020 to 30 August to 2 September 2020.
Kiadis Pharma Contact Maryann Cimino, Manager,
Corporate Affairs Tel: +1 (617) 710-7305 m.cimino@kiadis.com
About Kiadis Pharma’s K-NK-Cell Therapies
Kiadis Pharma’s NK-cell programs consist of off-the-shelf and haplo
donor cell therapy products for the treatment of liquid and solid
tumors as adjunctive and stand-alone therapies.
The Company’s NK-cell PM21 particle technology enables improved
ex vivo expansion and activation of anti-cancer cytotoxic NK-cells
supporting multiple high-dose infusions. Kiadis Pharma’s
proprietary off-the-shelf NK-cell platform is based on NK-cells
from unique universal donors. The Kiadis Pharma off-the-shelf K-NK
platform can make NK-cell therapy product rapidly and economically
available for a broad patient population across a potentially wide
range of indications.
Kiadis Pharma is clinically developing K-NK003 for the treatment
of relapse/refractory acute myeloid leukemia. The Company is also
developing K-NK002, which is administered as an adjunctive
immunotherapeutic on top of HSCT and provides functional, mature
and potent NK-cells from a haploidentical family member. In
addition, the Company has pre-clinical programs evaluating NK-cell
therapy for the treatment of solid tumors.
About Kiadis Pharma
Founded in 1997, Kiadis Pharma is building a
fully integrated biopharmaceutical company committed to developing
innovative therapies for patients with life-threatening diseases.
With headquarters in Amsterdam, the Netherlands, and offices and
activities across the United States, Kiadis Pharma is reimagining
medicine by leveraging the natural strengths of humanity and our
collective immune system to source the best cells for life.
Kiadis Pharma is listed on the regulated market
of Euronext Amsterdam and Euronext Brussels since July 2, 2015,
under the symbol KDS. Learn more at kiadis.com.
Forward Looking Statements Certain statements,
beliefs and opinions in this press release are forward-looking,
which reflect Kiadis Pharma or, as appropriate, Kiadis Pharma
officers’ current expectations and projections about future events.
By their nature, forward-looking statements involve a number of
known and unknown risks, uncertainties and assumptions that could
cause actual results, performance, achievements or events to differ
materially from those expressed, anticipated or implied by the
forward-looking statements. These risks, uncertainties and
assumptions could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
regulation, competition and technology, can cause actual events,
performance, achievements or results to differ significantly from
any anticipated or implied development. Forward-looking statements
contained in this press release regarding past trends or activities
should not be taken as a representation that such trends or
activities will continue in the future. As a result, Kiadis Pharma
expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or projections,
or any change in events, conditions, assumptions or circumstances
on which these forward-looking statements are based. Neither Kiadis
Pharma nor its advisers or representatives nor any of its
subsidiary undertakings or any such person’s officers or employees
guarantees that the assumptions underlying such forward-looking
statements are free from errors nor does either accept any
responsibility for the future accuracy of the forward-looking
statements contained in this press release or the actual occurrence
of the anticipated or implied developments. You should not place
undue reliance on forward-looking statements, which speak only as
of the date of this press release.